磷酸蛋白质组学
林恩
蛋白质组学
生物
癌症研究
蛋白质组
激酶
免疫印迹
磷酸化
转移
计算生物学
癌症
细胞生物学
蛋白质磷酸化
蛋白激酶A
生物信息学
原癌基因酪氨酸蛋白激酶Src
基因
生物化学
遗传学
作者
Nansong Xu,Changchun Lai,Qing‐Mei He,Yubo Cai,Yu Huang,Wenhao Zhong,Shulin Chen,Fang-Cai Wu,Hao Chen
出处
期刊:Life Sciences
[Elsevier]
日期:2023-11-01
卷期号:332: 122078-122078
标识
DOI:10.1016/j.lfs.2023.122078
摘要
Esophageal squamous cell carcinoma (ESCC) is one of the aggressive and lethal malignancies with an extremely poor prognosis. It is necessary to explore the molecular mechanisms of ESCC invasion.We utilized high-throughput mass spectrometry to analyze the proteomes and phosphorylation profiles of two ESCC cell lines with differing invasion capacities (HK vs TE10). Differentially expressed proteins and phosphorites were identified, followed by comprehensive bioinformatics analyses encompassing function and pathway enrichment, protein-protein interaction (PPI) network analysis, hub gene identification, co-expression analysis, kinase-substrate prediction, and drug-target network analysis. CCK-8 assay, transwell examination, wound-healing assay, and western blot was used to validate the effects of fostamatinib on ESCC cells proliferation, invasion, migration, and LYN expression.The Q4 cluster of differentially phosphorylated proteins was primarily associated with functions and pathways relevant to tumor metastasis. Phosphorylated hub proteins including ARHGAP35, CTNNA1, and SHC1 were identified through the analysis of PPI network, and their respective regulated kinases were predicted. Among the predicted kinases, LYN was validated to be associated with lymph node metastasis (N0 vs. N1-3) and prognosis in ESCC patients at mRNA levels using TGGA data and protein levels in ESCC tissues (p < 0.05). Validation experiments confirmed the inhibitory effects of fostamatinib on ESCC cells proliferation, migration, invasion, and LYN expression.Our multi-omics analysis offers deeper perspectives on ESCC invasiveness and unveils new phosphorylated hub proteins with their regulatory kinase. This study also suggests that fostamatinib may be a potential agent for treating ESCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI